Modality
Radioligand
MOA
USP1i
Target
B7-H3
Pathway
Sphingolipid
RSVGBM
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
Jan 2017
→ Jul 2027
Phase 1Current
NCT06457955
681 pts·RSV
2017-01→TBD·Active
NCT06981864
1,144 pts·GBM
2022-03→2027-07·Recruiting
1,825 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-07-031.3y awayPh2 Data· GBM
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P1/2
Active
P1/2
Recruit…
Catalysts
Ph2 Data
2027-07-03 · 1.3y away
GBM
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06457955 | Phase 1/2 | RSV | Active | 681 | HAM-D |
| NCT06981864 | Phase 1/2 | GBM | Recruiting | 1144 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 |